Organon & Co

OGN

Market cap $1.98B

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon and Henlius announce FDA approval of POHERDY, the first and only pertuzumab biosimilar in the US, which is interchangeable to Perjeta.

Organon & Co. faces ongoing challenges, with shares down over 75% since debut and recent CEO resignation after inventory probe. OGN Q3 results show stagnant revenues, declining Women's Health sales, and persistent high debt, despite low valuation metrics like a 3.7x forward P/E. Dividend has been slashed, Nexplanon sales fell 50% in the US in Q3, and the company is selling assets to manage leverage and cash flow issues.

Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon & Co. ( OGN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Carrie Cox Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply Matthew Walsh - Executive VP & CFO Conference Call Participants Jason Gerberry - BofA Securities, Research Division David Amsellem - Piper Sandler & Co., Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Terence Flynn - Morgan Stanley, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Hello, and welcome to the Organon Third Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations.

Organon (OGN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.87 per share a year ago.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025. “I am humbled to be working alongside our talented team during this pivotal time for Organon,” said Joe Morrissey, Organon's Interim Chief Executive Officer. “We are harnessing the company's many strengths, including a diverse portfolio that we expect will generate more than $900 million in free cash flow before one-time costs this year. We also remain committed to.